The MDS Beacon Staff's Archive
The MDS Beacon Staff has written 24 article(s).
This year’s American Society of Hematology (ASH) 2011 took place Saturday, December, 10, through yesterday in San Diego. This article summarizes the myelodysplastic syndromes-related highlights from Monday and yesterday.
Day 3
Monday was a busy day in terms of presentations related to myelodysplastic syndromes (MDS). There were several sessions with oral presentations throughout the day and a poster session in the evening.
The day began with a session about genetic alterations in MDS. During the session, researchers presented the latest…
Read the full story »
The American Society of Hematology (ASH) 2011 annual meeting is currently being held in San Diego. This article will summarize the myelodysplastic syndromes-related highlights from Saturday, the first full day of the conference, and Sunday, the second day of the meeting.
Day 1
Saturday started off with an education session on myelodysplastic syndromes (MDS) that consisted of three talks. The program was repeated in the afternoon.
The day ended with a large poster session, during which study results from…
Read the full story »
The U.S. Food and Drug Administration (FDA) on Friday approved the drug Ferriprox for the treatment of iron overload in patients with thalassemia who have had an insufficient response to at least one other iron overload therapy.
Thalassemia is a genetic condition that causes anemia.
The FDA approval of Ferriprox (deferiprone), which will be marketed by the Canadian company ApoPharma, is in line with the recommendation the agency received from its Oncology Drug Advisory Committee, which met last…
Read the full story »
FDA Advisory Committee Recommends Ferriprox For Accelerated Approval – The pharmaceutical company ApoPharma announced last week that the Oncologic Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) recommended that the FDA grant accelerated approval to the iron chelation agent Ferriprox (deferiprone). Specifically, the advisory committee recommended that Ferriprox receives accelerated approval for the treatment of patients with blood transfusion-related iron overload when current chelation therapy is inadequate. The FDA normally follows the recommendations of its…
Read the full story »